The Pharmaceutical Key Materials Innovation Center (KMIC) is dedicated to establishing a key materials platform for next-generation drug development, with a focus on providing critical small- and large-molecule materials for cutting-edge drug discovery and development. These include materials for PROTACs, molecular glues, covalent inhibitors, canonical nucleosides, and antibody–drug conjugate (ADC) linkers.
Building on expertise in medicinal chemistry, structural biology, and protein production, KMIC develops modular and systematic libraries of key materials to support the needs of academic, research, and biotechnology partners in early-stage drug discovery, drug design, and translational research. Through these capabilities, KMIC aims to accelerate drug development and advance the biotechnology industry in Taiwan.